Document:

Amendment to Employment Agreement, executed January 27, 2011

 Exhibit 10.2 
 AMENDMENT TO EMPLOYMENT AGREEMENT 
 This Amendment to Employment Agreement (the
“Amendment”), is effective as of October 1, 2010 (the “Effective Date”) between Ampio Pharmaceuticals, Inc., a Delaware corporation headquartered at 5445 DTC Parkway, PH 4, Greenwood Village, CO 80111, (hereinafter referred to as
the “Company”), and Vaughan Clift, M.D. (“Employee”). 
 RECITALS 

WHEREAS the Company and Employee are parties to that Employment Agreement effective as of August 1, 2010 (the “Agreement”); and

 WHEREAS the Company and Employee desire to amend the Agreement as stated in this Amendment; 

NOW, THEREFORE, the Company and Employee, for good and valuable consideration the receipt and sufficiency of which is acknowledged by each party,
agree that the Agreement shall be and hereby is amended as follows: 
  

	 	1.	Paragraph 3 (a) is amended and restated in its entirety as follows: 

 (a) Base Salary. The Company shall pay Employee a base salary of $198,000 per annum, payable at least monthly on the Company’s regular pay cycle for professional employees (the “Base
Salary”). In addition, the Company will continue to pay a $3,000 per month temporary housing allowance through the end of January 2011 or the date of a financing exceeding $5.0 million, whichever is later. Unless increased to such amount sooner
by the Company, effective the date of the completion of a financing exceeding $5.0 million, the Base Salary shall automatically increase, without additional action by the Compensation Committee or Board, to $250,000 per annum, payable as described
above. Except as specifically otherwise provided herein, the Base Salary may be increased only by recommendation of the Compensation Committee of the Board and ratified by the Compensation Committee or a majority of the independent members of the
Board. 
  

	 	2.	Promptly after completion of the equity financing presently contemplated by the Company (whether through use of SEC Form S-1 or otherwise), the Company shall pay
Employee an amount equal to the difference between Employee’s aggregate Base Salary from August 1, 2009 through the date of the completion of a financing exceeding $5.0 million and the amount that would have been paid to Employee had
Employee’s Base Salary been $198,000 per year for such period. 

  

	 	3.	The Company and Employee acknowledge and agree that the condition to effectiveness of the Agreement stated in Section 23 has been satisfied or waived by both parties.

  
 1 

 4. EXHIBIT A is amended and restated in its entirely as follows: 

EXHIBIT A 

Outside Activities 
  

	 	1.	Serve on the Board of Directors of no more than two private or public company, the business of which is not competitive with that of Ampio Pharmaceuticals, Inc.

  

	 	2.	Serve as a consultant to no more than two private or public companies, the business of which is not competitive with that of Ampio Pharmaceuticals, Inc.

  

	 	3.	Serve on the advisory boards of private or public companies whose identity is disclosed in writing to the Compensation Committee of the Board of Directors of Ampio
Pharmaceuticals, Inc. except where such disclosure would be in breach of Employee’s obligations under applicable federal laws or regulations pertaining to national security, the business of which is not competitive with that of Ampio
Pharmaceuticals, Inc. 

 Note: None of the possible outside activities may interfere with Employee’s best
efforts in meeting the responsibilities of Vice President of Scientific and Clinical Affairs of Ampio Pharmaceuticals, Inc., and will in the aggregate not require Employee to devote more than 10 hours per month to these outside activities.

  

	 	4.	The Company shall pay the reasonable expenses of Employee’s counsel in negotiating, preparing and revising this Amendment and advising Employee regarding the same.

  

	 	5.	Sections 10 through 22, excluding Section 20, of the Agreement are incorporated in this Amendment as if set forth in full herein. 

 IN WITNESS WHEREOF, the parties hereto have executed this Amendment as of the date first written
above. 
  

							
	AMPIOPHARMACEUTICALS, INC.	 		 	EMPLOYEE
				
	By:	 	 /s/ Philip H. Coelho
	 		 	 /s/ Vaughan Clift, M.D.

	Philip H. Coelho	 		 	Vaughan Clift, M.D.
	 Chairman, Compensation Committee
 Board of Directors
	 		 	
			
	Date: 1/27/2011                       
                               	 		 	Date: 1/27/2011                        
                            
				
	By:	 	 /s/ Donald B. Wingerter, Jr.
	 		 	
	Donald B. Wingerter, Jr.	 		 	
	Chief Executive Officer	 		 	
			
	Date: 1/27/2011                        
                              	 		 	
			
	Signed in counterpartsExtension Agreement for Related Party Debenture issued to Michael Macaluso

 Exhibit 10.3 
 AMPIO PHARMACEUTICALS, INC. 
 EXTENTION AGREEMENT FOR NOTES PAYABLE

 TOTAL PRINCIPAL AMOUNT: $230,000 
 Effective Date: January 31, 2011 
 Greenwood Village, CO 80111 

On August 12, 2010 and August 16, 2010, the undersigned Ampio Pharmaceuticals, Inc., a Delaware corporation (the “Maker”), issued two
promissory notes (the “Notes”) in the amounts of $30,000.00 and $200,000.00, respectively, and promised to pay to the order of Michael Macaluso, and his successors or assigns (collectively, the “Holder”), the aggregate sum of
$230,000.00 due under the Notes, together with interest at the rate of 8.0% (eight percent) per annum until the Notes are paid in full. The Notes were originally due on January 31, 2011. 
 In consideration of this extension agreement, the payment of $100, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged and accepted by the Holder and
the Maker, the Maker and the Holder hereby agree to extend the due date of the Notes to the earlier of (i) closing of a public or private equity financing (the “Offering”) in an amount exceeding $5 million, or (ii) April 30,
2011. All of the other terms of the original Notes remain unchanged. 
 Maker may prepay the Notes in part, or in full, prior to the due date of
the Notes. Payments of principal and interest shall be made at the place that Holder from time to time shall direct in writing. 
 In witness
whereof, the parties hereto have executed this Extension Agreement for Notes Payable, to be effective the date specified above. 
 Maker:

 Ampio Pharmaceuticals, Inc. 
  

			
	By:	 	 /s/ Donald B. Wingerter

		 	Donald B. Wingerter, Chief Executive Officer

 Holder:

 Michael Macaluso 
  

			
	By:	 	 /s/ Michael Macaluso

		 	Michael MacalusoExtension Agreement for Related Party Debenture issued to Richard Giles

 Exhibit 10.4 
 AMPIO PHARMACEUTICALS, INC. 
 EXTENTION AGREEMENT FOR NOTES PAYABLE

 TOTAL PRINCIPAL AMOUNT: $100,000 
 Effective Date: January 31, 2011 
 Greenwood Village, CO 80111 

On August 10, 2010, the undersigned Ampio Pharmaceuticals, Inc., a Delaware corporation (the “Maker”), issued one promissory note (the
“Note”) in the amount of $100,000.00, and promised to pay to the order of Richard B. Giles, and his successors or assigns (collectively, the “Holder”), the aggregate sum of $100,000.00 due under the Note, together with interest
at the rate of 8.0% (eight percent) per annum until the Note is paid in full. The Note was originally due on January 31, 2011. 
 In
consideration of this extension agreement, the payment of $100, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged and accepted by the Holder and the Maker, the Maker and the Holder hereby agree
to extend the due date of the Notes to the earlier of (i) closing of a public or private equity financing (the “Offering”) in an amount exceeding $5 million, or (ii) April 30, 2011. All of the other terms of the original
Notes remain unchanged. 
 Maker may prepay the Notes in part, or in full, prior to the due date of the Notes. Payments of principal and
interest shall be made at the place that Holder from time to time shall direct in writing. 
 In witness whereof, the parties hereto have
executed this Extension Agreement for Notes Payable, to be effective the date specified above. 
 Maker: 

Ampio Pharmaceuticals, Inc. 
  

			
	By:	 	 /s/ Donald B. Wingerter

		 	Donald B. Wingerter, Chief Executive Officer

 Holder:

 Richard B. Giles 
  

			
	By:	 	 /s/ Richard B. Giles

		 	Richard B. GilesExtension Agreement for Related Party Debenture issued to James Ludvik

 Exhibit 10.5 
 AMPIO PHARMACEUTICALS, INC. 
 EXTENTION AGREEMENT FOR NOTES PAYABLE

 TOTAL PRINCIPAL AMOUNT: $100,000 
 Effective Date: January 31, 2011 
 Greenwood Village, CO 80111 

On August 10, 2010, the undersigned Ampio Pharmaceuticals, Inc., a Delaware corporation (the “Maker”), issued one promissory note (the
“Note”) in the amount of $100,000.00, and promised to pay to the order of James Ludvik, and his successors or assigns (collectively, the “Holder”), the aggregate sum of $100,000.00 due under the Note, together with interest at
the rate of 8.0% (eight percent) per annum until the Note is paid in full. The Note was originally due on January 31, 2011. 
 In consideration
of this extension agreement, the payment of $100, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged and accepted by the Holder and the Maker, the Maker and the Holder hereby agree to extend the
due date of the Notes to the earlier of (i) closing of a public or private equity financing (the “Offering”) in an amount exceeding $5 million, or (ii) April 30, 2011. All of the other terms of the original Notes remain
unchanged. 
 Maker may prepay the Notes in part, or in full, prior to the due date of the Notes. Payments of principal and interest shall be
made at the place that Holder from time to time shall direct in writing. 
 In witness whereof, the parties hereto have executed this Extension
Agreement for Notes Payable, to be effective the date specified above. 
 Maker: 
 Ampio Pharmaceuticals, Inc. 
  

			
	By:	 	 /s/ Donald B. Wingerter

		 	Donald B. Wingerter, Chief Executive Officer

 Holder:

 James Ludvik 
  

			
	By:	 	 /s/ James Ludvik

		 	James Ludvik

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00184-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00184-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00184-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00184-of-00352.parquet"}]]